ATTENTION deficit hyperactivity
disorder (ADHD) may be the
subject of overprescription and
overdiagnosis with the implication
that disorders of children in
particular are being “medicalised”,
according to an editorial in the
MJA.
There are risks for children that
the use of stimulant medication is a
“simplistic attempt to find solutions
to more complex problems
underlying behavioural and
emotional difficulties, and risks in
adolescents and adults prescribed
or exposed to stimulants, including
poisonings,” the article states.
The author suggests that
prescription monitoring programs
may have a role to play, although
this has not generally been
successful in Australia as yet.The above article was sent to subscribers in Pharmacy Daily's issue from 08 Mar 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Mar 16
PEAK pharmacy bodies are calling on the Australian Government to extend the new Commonwealth Prac Payment to pharmacy students, citing the challenges of “placement poverty” in unpaid practical placements.
AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ’s Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.